Kayexalate Dosing for Hyperkalemia
The recommended dose of Kayexalate (sodium polystyrene sulfonate) for hyperkalemia is 15-50 g plus sorbitol per oral or per rectum. 1
Adult Dosing
- Oral administration: 15 g (60 mL) to 60 g (240 mL) of suspension daily, typically given as 15 g (60 mL) one to four times daily 2
- Rectal administration: 30 g (120 mL) to 50 g (200 mL) every six hours 2
Pediatric Dosing
- Oral: 1 g/kg up to 15 g (60 mL) every 6 hours as needed 1
- Rectal: 1 g/kg up to 50 g every 6 hours as needed 1
Administration Guidelines
Oral Administration
- Administer at least 3 hours before or 3 hours after other oral medications
- Patients with gastroparesis may require a 6-hour separation 2
- Administer with patient in upright position
- May be introduced through a nasogastric tube if necessary
Rectal Administration
- After initial cleansing enema, insert a large size (French 28) rubber tube into the rectum for about 20 cm
- Introduce suspension at body temperature by gravity
- Flush with 50-100 mL of fluid
- Keep in sigmoid colon for several hours if possible
- Follow with sodium-free cleansing enema 2
Important Warnings and Precautions
Risk of GI necrosis: Kayexalate, especially when combined with sorbitol, has been associated with intestinal necrosis, which can be fatal 3, 4
Electrolyte disturbances:
Special populations:
Efficacy considerations:
Alternative Treatments for Hyperkalemia
For severe hyperkalemia, consider a stepwise approach:
Stabilize myocardial cell membrane:
- Calcium chloride (10%): 5-10 mL IV over 2-5 minutes, or
- Calcium gluconate (10%): 15-30 mL IV over 2-5 minutes
Shift potassium into cells:
- Sodium bicarbonate: 50 mEq IV over 5 minutes
- Glucose plus insulin: 25 g glucose and 10 U regular insulin IV over 15-30 minutes
- Nebulized albuterol: 10-20 mg over 15 minutes
Promote potassium excretion:
- Diuresis: furosemide 40-80 mg IV
- Kayexalate: 15-50 g plus sorbitol PO or PR
- Dialysis (for severe cases) 1
Efficacy Evidence
A randomized clinical trial demonstrated that sodium polystyrene sulfonate (30 g daily for 7 days) was superior to placebo in reducing serum potassium levels in patients with mild hyperkalemia and CKD (mean difference between groups: -1.04 mEq/L) 6.
However, newer potassium binders may offer advantages over Kayexalate, including faster onset of action, better selectivity for potassium, and potentially improved safety profiles 1.